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ttp://dx.doi.org/10.1016/j.ajpath.2015.01.029Breast cancer metastasis is the leading cause of cancer-related deaths in women worldwide. Collagen in
the tumor microenvironment plays a crucial role in regulating tumor progression. We have shown that type
III collagen (Col3), a component of tumor stroma, regulates myoﬁbroblast differentiation and scar for-
mation after cutaneous injury. During the course of these wound-healing studies, we noted that tumors
developed at a higher frequency in Col3þ/ mice compared to wild-type littermate controls. We, there-
fore, examined the effect of Col3 deﬁciency on tumor behavior, using the murine mammary carcinoma cell
line 4T1. Notably, tumor volume and pulmonary metastatic burden after orthotopic injection of 4T1 cells
were increased in Col3þ/ mice compared to Col3þ/þ littermates. By using murine (4T1) and human
(MDA-MB-231) breast cancer cells grown in Col3-poor and Col3-enriched microenvironments in vitro, we
found that several major events of the metastatic process were suppressed by Col3, including adhesion,
invasion, and migration. In addition, Col3 deﬁciency increased proliferation and decreased apoptosis of
4T1 cells both in vitro and in primary tumors in vivo. Mechanistically, Col3 suppresses the procarcinogenic
microenvironment by regulating stromal organization, including density and alignment of ﬁbrillar
collagen and myoﬁbroblasts. We propose that Col3 plays an important role in the tumor microenvironment
by suppressing metastasis-promoting characteristics of the tumor-associated stroma. (Am J Pathol 2015,
185: 1471e1486; http://dx.doi.org/10.1016/j.ajpath.2015.01.029)Supported by National Institute of Arthritis and Musculoskeletal and
Skin Diseases grant K08AR053945, the Mari Lowe Center for Comparative
Oncology at the University of Pennsylvania School of Veterinary Medicine,
a Jack Miller-Ebrahimi Foundation gift (S.W.V.), and NIH grants
DK058123 (R.G.W.), R01CA180070, and RO1CA141144 (E.P.), and
S10RR027128 (which funded Bruce D. Freedman for instrumentation in
the Penn Vet Imaging Core facility).
Disclosures: None declared.Breast cancer is themost frequently diagnosed cancer inwomen
and is the leading cause of cancer-related deaths in women
worldwide (World Health Organization: Latest World Cancer
Statistics. 2013, Press Release Number 223, http://www.iarc.fr/
en/media-centre/pr/2013/pdfs/pr223_E.pdf). In fact,>500,000
women are predicted to die this year alone. Without major
changes in prevention or treatment, those numbers are
anticipated to nearly double in 20 years. In most patients,
death is not caused by the primary tumor, but rather by
metastases. The extracellular matrix (ECM) of the tumor
microenvironment plays a critical role in cancer develop-
ment and progression through its ability to modulate
physical, biochemical, and biomechanical cues perceived
by both tumor cells and cancer-associated stromal cells.1e3
Given this critical role of the ECM and tumor stromal cellsstigative Pathology.
.in breast cancer development and progression, it is not
surprising that recent studies suggest that targeting the
tumor stroma is a potential therapeutic strategy for tumor
control.4e6 However, optimization of such strategies re-
quires a better understanding of the mechanistic role that
individual stromal components play in regulating tumor
cell behavior.
Brisson et alCollagen, a major component of the ECM, is increasingly
recognized to play a key role in regulating breast cancer
progression. Although most research on collagen in breast
cancer has focused on type I collagen (Col1), and many
reports have documented a negative correlation between
Col1 expression and prognosis in breast cancer patients,
collagen types IV, V, VI, and XVIII have also been impli-
cated in modulation of breast cancer cell activities and
fate.7e12 Increased collagen density in the tumor stroma can
promote invasion and metastasis of breast cancer
cells.4,13e15 In addition, differences in the organization
and stiffness of the tumor stroma are known to inﬂuence
tumor cell responses and stromal remodeling, a key step in
metastasis.15e24 In fact, targeting collagen in the tumor
stroma can effectively reduce pulmonary metastasis in
breast cancer models.4,6
In contrast to the documented procarcinogenic effects of
Col1, a gap in knowledge exists regarding the role for the
related ﬁbrillar type III collagen (Col3) in breast cancer. Col3
plays a critical function in tissue and organ maintenance, in
part through its ability to regulate Col1 ﬁbrillogenesis.25 We
have identiﬁed a role for Col3, distinct from Col1, in pro-
moting a regenerative wound-healing response after cutaneous
injury. Speciﬁcally, we showed that Col3 promotes reepithe-
lialization and suppresses scar formation through its ability to
limit the density of myoﬁbroblasts, the key cellular effectors of
scar formation/ﬁbrosis, within wound granulation tissue.26
Given the long-standing view of cancer as wounds that do
not heal and the more recently described wound healing,
chronic ﬁbrosis, and cancer progression triad,27,28 we hy-
pothesized that diminished Col3 in the tumor microenviron-
ment would drive aggressive cancer behaviors and promote
metastasis. Because many of the same cells and extracellular
proteins (eg, collagens and growth factors) that cause wound
healing to go awry also drive aggressive cancer behavior,27,28
it is noteworthy that myoﬁbroblasts and a ﬁbrotic healing
response characteristic of Col3-deﬁcient wounds have both
been implicated in breast cancer metastasis.29e31 Consistent
with our hypothesis that Col3 loss promotes aggressive breast
cancer behaviors, recent data show that a robust stromal
response that includes increased Col3 expression correlates
with improved survival of breast cancer patients.32
Herein, we present in vitro and in vivo evidence that Col3
plays an important role in suppressing breast cancer growth and
metastasis, using murine (4T1) and human (MDA-MB-231)
metastatic triple-negative breast cancer cell lines, a cancer
type with limited effective treatment options. Speciﬁcally,
we show that Col3 is a critical regulator of tumor stroma
organization and that diminished levels of Col3 promote
tumor cell survival, proliferation, and key processes in
metastasis (adhesion, invasion, and migration). Collectively,
our ﬁndings show that Col3 suppresses procarcinogenic
behavior of breast cancer cells to limit primary tumor growth
and metastasis and suggest that a Col3-deﬁcient tumor
microenvironment promotes metastasis, in part, through the
impact of Col3 on stromal organization.1472Materials and Methods
Col3-Deﬁcient Mice
Animal use and care were approved by the Institutional
Animal Care and Use Committee of the University of
Pennsylvania (Philadelphia) and followed guidelines set
forth in the NIH Guide for the Care and Use of Laboratory
Animals.33 All mice for this study were generated in a
colony established at the University of Pennsylvania from
breeder pairs of Col3a1 heterozygous (Col3þ/) mice
originally purchased from Jackson Laboratories (Bar Har-
bor, ME). These mice had been generated by homologous
recombination by replacement of the promoter region and
ﬁrst exon of the Col3 gene with a 1.8-kb PGKneo cassette,25
generating a global knockout. Animals were genotyped for
Col3 by PCR analysis of DNA extracted from tail biopsy
specimens and were microchipped for identiﬁcation (Allﬂex
FDX-B transponders; Allﬂex USA, Inc., Dallas, TX).26,34
All mice in the Col3 colony, regardless of the study they
were used for, were surveyed routinely for general health and
pathology, including gross evidence of tumor development.
Once a trend was recognized for an increase in tumor for-
mation in Col3þ/ mice, all mice dying spontaneously or
euthanized at>1 year of age had a gross necropsy performed,
and a biopsy of any abnormal masses was performed. His-
topathological diagnoses of tumor biopsy specimens were
made by a board-certiﬁed veterinary pathologist (E.A.M.).
Cell Culture and Tumor Generation
4T1 and 4T1egreen ﬂuorescent protein (GFP) cell lines
(obtained from Dr. Lalage Wakeﬁeld at the National Cancer
Institute, Bethesda, MD, in 201035) and MDA-MB-231 cells
[obtained from Dr. Meenhard Herlyn (Wistar Institute, Phil-
adelphia, PA) in 201236] were authenticated by morphology,
growth characteristics, and biological behavior, tested for
Mycoplasma, and frozen. Cells were cultured for<4 months.
All cells were cultured in growth media: Dulbecco’s modiﬁed
Eagle’s medium (Glutamax; Gibco, Grand Island, NY) sup-
plemented with 10% fetal bovine serum (Atlanta Biologicals,
Flowery Branch, GA) and antibiotics (100 U/mL penicillin
and 100 g/mL streptomycin). GFP expression in the 4T1-GFP
cell line was preserved with inclusion of 50 mg/mL G418
(Geneticin, Life Technologies, Carlsbad, CA) in the
growth media.
For orthotopic tumor implantation, 0.1 or 0.5  106 4T1
cells [in 0.1 mL sterile phosphate-buffered saline (PBS)]
were injected s.c. into the right fourth mammary fat pad of
anesthetized mice (aged 8 to 20 weeks). Tumor volume was
calculated using the following formula: V Z (L  W2)/2.37
Tissue Processing
Primary tumors, mammary fat pads, and lungs were
collected and ﬁxed in Prefer Fixative (Anatech LTD, Battleajp.amjpathol.org - The American Journal of Pathology
Col3 Suppresses Breast Cancer MetastasisCreek, MI). Before ﬁxation, lungs were perfused through
the heart and trachea. Tissues were parafﬁn embedded and
processed, and serial sections (4 mm thick) were stained with
hematoxylin and eosin (H&E), as previously described.26
Analysis of Pulmonary Metastases
After perfusion and ﬁxation, gross lung metastases in mice
with orthotopic 4T1 tumorswere counted.All lung lobeswere
bisected lengthwise through the main stem bronchi.38 Quan-
titation of metastasis on H&E-stained slides containing a
cross section of all ﬁve lung lobes was performed by a
pathologist (E.A.M.). Lung tumor burden was quantitated
using ImageJ software version 1.48 (NIH, Bethesda, MD), as
previously described.39 To examine how Col3 in the meta-
static niche regulates metastasis, tail vein injections and
analysis of pulmonary colonization were performed. Specif-
ically, 7- to 11-week-old male mice were injected with
1.0  106 4T1-GFP cells (via tail vein). After 24 hours, the
mice were sacriﬁced, and the lungs were perfused with PBS.
A single-cell suspension was collected after treating the lungs
with a mixture of collagenases. Cells were stained with pro-
pidium iodine and analyzed via ﬂow cytometry using a
LSRFortessa (BD Biosciences, Bedford, MA). The percent-
age of live (propidium iodineenegative) 4T1 (GFP-positive)
cells within the lung was calculated.
Tissue Immunohistochemistry and
Immunoﬂuorescence
Sections from ﬁxed, parafﬁn-embedded tissues were moun-
ted onto charged glass slides. After deparafﬁnization and
rehydration, antigen retrieval was performed by citrate buffer
boiling or incubation with proteinase K (20 mg/mL in Tris-
ethylenediaminetetraacetic acid buffer for Col3 staining).
For immunohistochemistry, sections were blocked in 3%
H2O2, PBS containing 1% bovine serum albumin (A5611;
Sigma-Aldrich, St. Louis, MO), 10% goat serum, avidin
blocking solution, and biotin blocking solution (Avidin
Blocking Kit; Vector Laboratories Inc., Burlingame, CA).
For immunoﬂuorescence, sections were blocked in PBS
containing 5% bovine serum albumin, 5% goat serum, and
0.05% Tween-20 (Bio-Rad, Hercules, CA). Slides were
incubated with antibodies directed against Col3 (ab7778;
Abcam, Cambridge, MA), Ki-67 (ab15580; Abcam), active
caspase 3 (9664; Cell Signaling, Danvers, MA), or a-
smooth muscle actin (a-SMA; ab5694; Abcam). Slides were
then incubated in secondary antibody, biotin-goat anti-rabbit
IgG (BA 1000; Vector Laboratories Inc.), then incubated in
tertiary antibody (ABC elite; Vector Laboratories Inc.) and
incubated in DABþ Substrate (Dako, Carpinteria, CA) until
brown color developed. Slides were counterstained in he-
matoxylin, before dehydration and mounting.
For immunoﬂuorescence, sections were incubated with an
Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen, Grand
Island, NY) and mounted in medium containing DAPIThe American Journal of Pathology - ajp.amjpathol.org(Vector Laboratories Inc.). All slides were viewed with an
Olympus BX51 microscope (Olympus, Melville, NY), and
digital images were obtained using a constant exposure
threshold. For active caspase 3 and a-SMA staining quanti-
ﬁcation, ImageJ software was used to measure the percentage
area of the image that contained positive staining. The
proliferative index was calculated using ImageJ software
(percentage of Ki-67epositive nuclei/total nuclei).
Quantitative Real-Time PCR
mRNA expression analysis was performed as previously
described.34 Brieﬂy, RNAwas extracted from ﬁbroblasts, 4T1
cells, and mouse tissues [mammary fat pads and lungs from
tumor-naïve mice and tumors (14 days after orthotopic injec-
tion of 4T1 cells)], cDNA was generated, and Col1 and Col3
expression was compared to glyceraldehyde-3-phosphate de-
hydrogenase as the endogenous control. For mouse tissues,
lungs from young (16 to 18 weeks old) and aged (92 to 94
weeks old), and fat pads and tumors from young (10 to 24
weeks old), mice were used.
Fibroblast Isolation and Culture
Embryonic ﬁbroblasts were harvested and genotyped as
described previously.26 Fibroblasts were cultured and passaged
(passage 6 or less), as described for 4T1 cells, including the
addition of L-ascorbic acid (A8960; Sigma-Aldrich) to the
growth media to ensure secretion of a collagen-rich matrix.
Generation of Fibroblast-Derived Matrices
Decellularized matrices were generated, as previously de-
scribed,40 using E18.5 embryonic ﬁbroblasts. After 5 to 8
days in culture, thematriceswere decellularized andwere either
stored in PBS at 4C or used immediately for experiments.
Proliferation Assays
Fibroblast-derived matrices were generated in 96-well plates
(1.0  104 ﬁbroblasts per well), as described above. 4T1
(1.5  104) or MDA-MB-231 (2.5  104) cells were plated
and cultured on these decellularized matrices in growth media
for 6 hours before changing to serum-free media overnight.
Proliferation was measured using a bromodeoxyuridine,
96-well, enzyme-linked immunosorbent assayebased assay
(QIA58; EMD Millipore, Billerica, MA), using a Varioskan
Flash plate reader (Thermo Fisher Scientiﬁc, Waltham, MA).
Analysis of Apoptotic Cells
4T1 or MDA-MB-231 cells (1.0  104) were plated onto
ﬁbroblast-derived matrix-coated coverslips in 24-well plates,
cultured in growth media for 16 hours, and then switched to
serum-free media for 48 hours. After ﬁxation with 4%
paraformaldehyde, coverslips were incubated with an1473
Brisson et alantibody directed against active caspase 3 (ab2302; Abcam)
and subsequently with an Alexa Fluor 488 donkey anti-rabbit
antibody (Invitrogen), before mounting in medium contain-
ing DAPI. Fluorescence was viewed as described above for
sections.
Adhesion Assays
For assessment of Col3 modulation of 4T1 morphology and
adhesion, ﬁbroblasts (5.0  104) were plated and cultured in
24-well plates for 48 hours in growth media before subsequent
seeding of 4T1-GFP cells (8.0  105). 4T1-GFP cells were
allowed to adhere for 2 hours in growth media or remain in
culture for 48 hours in serum-freemedia to assessmorphology,
then ﬁxed and imaged. For adhesion, GFP intensity was
quantitated using ImageJ software. For adhesion in collagen-
coated wells, 24-well plates were coated with 0.5 mg/cm2
human placenta-derived (hP) collagens hPCol1 (354243; BD
Biosciences), hPCol3 (354244; BD Biosciences), or a 50:50
(0.5 mg/cm2 total collagen) or 100:50 (0.75 mg/cm2 total
collagen) mixture of both. 4T1 cells (5.0 105) were plated in
growth media and allowed to adhere for 2 hours. Attached
cells were stained with crystal violet, and OD 570 was
measured using a Varioskan plate reader. For adhesion to a
substratum with stiffness similar to mammary fat pad,41
hydrogels (6 kPa) were generated as described previously42
on 12-mm coverslips in 24-well plates. The hydrogels were
coated with hPCol1 and hPCol3 at 0.03 mg/mL or a 50:50
mixture of both. 4T1-GFP cells were allowed to attach as
described above, and GFP intensity (509 nm) was read in a
Varioskan plate reader. Data between separate experiments
were normalized to gels coated with rat tail collagen (354236;
BD Biosciences). For MDA-MB-231 adhesion in collagen-
coated wells, MDA-MB-231 cells (2.5  105) were plated in
growth media and allowed to adhere for 1 hour, and analyzed
as above for 4T1 cells.
Invasion and Migration Assays
Migration was assessed in 24-well Transwell plates
(353097; BD Biosciences) that were coated with 1 mg/cm2
recombinant human Col1 (354254; BD Biosciences), re-
combinant human Col3 (354255; BD Biosciences), or a
50:50 mixture of both. 4T1 or MDA-MB-231 cells
(5.0  105) were plated in the upper chambers in serum-free
media and allowed to migrate for 20 hours (lower chamber
contained growth media). Cells collected from the bottom of
the porous membrane were stained with crystal violet,
which was quantitated as above. Invasion was assessed
similarly, except that the collagens were added to Matrigel
(354230; BD Biosciences) used to coat the top of the
membranes before cell seeding. Cancer cells that invaded
through the collagen-supplemented simulated basement
membrane were quantitated as described above. For MDA-
MB-231 invasion and migration, hPCol1, hPCol3, or a
50:50 mixture of both was used.1474Second Harmonic Generation and Collagen Fiber
Analysis
Imaging of ﬁbrillar collagen was performed on a Leica SP5
confocal/multiphoton microscope (Leica Microsystems, Inc.,
Mannheim, Germany) by tuning the Coherent ChameleonUltra
II Ti:Sapphire laser (Coherent Inc., Santa Clara, CA) to 800 nm
and collecting second harmonic (SHG) signal on a non-
descanned detector conﬁgured to capture wavelengths <495
nm. To distinguish true SHG signal from autoﬂuorescence,
ﬂuorescence images at wavelengths of 495 to 560 nm (green
autoﬂuorescence) and 560 to 620 nm (red autoﬂuorescence)
were simultaneously acquired on two additional nondescanned
detectors and subtracted from the original SHG image.
Collagen signal and orientation were analyzed as described
previously,43 with few modiﬁcations. ImageJ software was
used to calculate the percentage of the images that contained
SHG-positive pixels, as a measure of collagen ﬁber intensity.
ImageJ software was then used to generate a fast Fourier
transform powerplot of the ﬁbrillar collagen signal. An ellipse
was superimposed over the positive signal, and the major and
minor axes of the ellipse weremeasured. An aspect ratio (major/
minor axis) with a smaller value indicated random orientation,
and larger values indicated orientated, aligned collagen ﬁbers.
For quantiﬁcation of tumor-associated collagen signature
(TACS), ﬁbers at the tumor boundary were analyzed using
CurvAlign software (http://loci.wisc.edu/software/curvealign,
last accessed December 31, 2014; version 3.0, beta 2). The sum
of all collagen ﬁbers with angles between 0 and 30 degrees from
the tumor boundary was considered to be TACS-2, and ﬁbers
with angles between 60 and 90 degrees were classiﬁed as
TACS-3, as previously described.44
Data Analysis
Values are expressed as means  SD, unless otherwise
stated. A one-tailed Fisher’s exact test was performed to
compare spontaneous tumor incidence between Col3þ/þ and
Col3þ/ mice. For in vivo experiments, unpaired Student’s
t-tests were used to determine the signiﬁcance of differences
between mouse genotypes. For in vitro analyses, paired
t-tests were used to compare ﬁbroblasts from littermate
embryos that were isolated, cultured, frozen, and passaged
together. One-way analyses of variance, followed by Tukey
post hoc tests, were used to compare cancer cell properties
on different collagens. Study groups were compared using
GraphPad Prism 5 statistical software (La Jolla, CA).
P < 0.05 was considered statistically signiﬁcant.
Results
Col3 Haploinsufﬁciency Promotes Development of
Spontaneous Neoplasia
During our original wound-healing studies,26 we noted that
spontaneous tumors developed more frequently in aged (>1ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Expression of Col3þ/ is reduced in fat pads from Col3 mice compared to wild-type (Col3þ/þ) mice. A: Images of skin and adjoining s.c. fat
from fat pads stained with hematoxylin and eosin. B: Serial sections from A stained for Col3. Left panel: Isotype control. Middle panel: Col3-stained
Col3þ/þ tissue sections. Right panel: Col3-stained Col3þ/ tissue sections. Boxed areas are enlarged in C and D. C: Images of Col3-stained dermis. D:
Images of Col3-stained fat. E: mRNA expression of Col3 from mammary fat pads relative to Col3þ/þ fat pads. F: Images of Col3-stained mammary glands
within the mammary fat pad. Representative images shown (AeD and F). Data represent means  SEM (E). n Z 4 Col3þ/þ and Col3þ/ (E). *P < 0.05
(E). Scale bars: 100 mm. Original magniﬁcations: 10 (A); 60 (C, D, and F).
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Brisson et alyear) femaleCol3þ/mice compared to age- and sex-matched
wild-type littermates [12/73 (16.4%) Col3þ/ mice versus
3/58 (5.2%) Col3þ/þ mice; P < 0.05]. Histopathology
conﬁrmed the diagnosis of neoplasia in all masses on which
a biopsy was performed (13 masses total) (Supplemental
Table S1). Although a variety of tumor types were repre-
sented, mammary carcinoma was found in two Col3þ/mice
(Supplemental Figure S1). Given the increased incidence of
spontaneous tumor development in Col3þ/ mice and the
potential role of Col3 in suppressing aggressive breast cancer
behavior in women,32 we initiated a study to examine mam-
mary tumor growth and metastasis in Col3-deﬁcient mice,
using the syngeneic 4T1 model of breast cancer.35,45
Col3 Haploinsufﬁciency Promotes Primary Tumor
Growth and Metastasis
Liu et al25 previously generated Col3/ mice by homologous
recombination, replacing the promoter and the ﬁrst exon of the
Col3a1 gene with a neomycin cassette. Because these global
knockout mice rarely survive beyond the perinatal period,25 we
used Col3-haploinsufﬁcient mice, which have been conﬁrmed
to express50%Col3 in all tissues examined,25,34,46,47 to study
the effects of Col3 on mammary tumor development. Fibrillar
collagens, including Col3, are ECM components of normal
human and rodent mammary tissue.48,49 Immunohistochemical
localization of Col3 within the skin and underlying s.c. fat,
including mammary tissue, in Col3þ/þ mice revealed Col3
staining surrounding blood vessels and within the dermis,
periadipocyte matrix, and the intralobular stroma of mammary
ducts (Figure 1). By comparison, Col3 immunostaining
appeared less pronounced in sections from tissues harvested
from Col3þ/ mice. Quantitative real-time PCR conﬁrmed a
signiﬁcant reduction in Col3 expression in the mammary fat
pad of young adult Col3þ/ mice compared to wild-type
littermates (P < 0.05).
To determine whether diminished levels of Col3 drive
aggressive tumor behaviors, 4T1 cells were injected ortho-
topically in Col3 wild-type and haploinsufﬁcient littermates,
and primary tumor growth and metastasis were assessed.
Primary tumor size was measured every 2 to 3 days after
injection of 4T1 cells into either Col3þ/þ or Col3þ/ mice.
By day 21, primary tumors in Col3þ/ mice were twice as
large as tumors in Col3þ/þ mice (Figure 2A). Both the
cumulative effect of Col3 deﬁciency on 4T1 tumor growth,
analyzed by measuring the area under the curve for each
tumor50 and the tumor mass at the study end point (day 24)
(Figure 2, B and C), conﬁrmed that tumor growth is
signiﬁcantly increased by Col3 deﬁciency.
Becausemortality in breast cancer patients is almost always
associated with metastases rather than the primary tumor, we
investigated whether Col3 deﬁciency also increased pulmo-
nary metastasis in the 4T1 breast cancer model (Figure 2,
DeH). Quantitative analysis revealed a nearly threefold in-
crease in gross metastases in Col3þ/ compared to Col3þ/þ
lungs (P < 0.05) (Figure 2F). Quantitative histological1476assessment of H&E-stained lung sections conﬁrmed that both
the number of metastatic nodules and the tumor burden
(% total lung area) were signiﬁcantly greater in Col3þ/mice
compared to Col3þ/þ littermates (Figure 2, G and H).
We next investigated whether diminished Col3 in the pre-
metastatic niche (lung) of Col3þ/ mice increased pulmonary
parenchymal colonization of metastasized cells. Collagen,
including Col3, is a normal component of the lung, with Col3
expression attributed to pulmonary ﬁbroblasts in several stud-
ies.51e53 As anticipated in this global knockout Col3 strain,
pulmonary Col3 was signiﬁcantly reduced in Col3þ/ mice
compared to Col3þ/þ littermates (Figure 3A). As suggested by
previous studies examining the effect of age on Col3
expression,34,54e57 advanced age (>23 months) is associated
with a reduction in pulmonary Col3 mRNA expression
(P < 0.01). To assess whether reduced pulmonary Col3 could
inﬂuence tumor colonization of the lungs, 4T1-GFP cells were
injected via the tail vein into young adult Col3þ/þ and Col3þ/
mice. After 24 hours, the percentage of GFP-positive live cells
in single lung cell suspensions was quantitated by ﬂow
cytometry (Figure 3, B and C). There was no signiﬁcant dif-
ference between cells colonizing lungs of Col3þ/þ andCol3þ/
mice, suggesting that Col3 limits pulmonary metastasis pri-
marily through another mechanism, such as a gatekeeper effect
at the level of the primary tumor site. Taken together, our re-
sults identify a previously unrecognized role for Col3 as a
suppressor of breast cancer growth and metastasis and distin-
guish the effects of Col3 from the procarcinogenic effects of
Col1 in the tumor microenvironment.
Col3 Deﬁciency Promotes Proliferation and Inhibits
Apoptosis of Breast Cancer Cells
An increase in proliferation, a decrease in apoptosis, or both
could mediate the accelerated primary tumor growth seen in
Col3þ/ mice. To differentiate between these possibilities,
we examined bromodeoxyuridine incorporation and active
caspase 3 activity in 4T1 cells cultured on wild-type and
Col3-deﬁcient cell-derived matrices in vitro. Col3-deﬁcient
decellularized matrices were prepared from Col3/ em-
bryonic ﬁbroblasts, because culture and passage could
potentially induce variations in Col3 production by Col3þ/
ﬁbroblasts. Increased bromodeoxyuridine incorporation was
observed in 4T1 cells cultured on Col3/ ﬁbroblast-derived
matrices, relative to that seen with cells cultured on Col3þ/þ
ﬁbroblast-derived matrices (P < 0.05) (Figure 4A). In addi-
tion, there was a signiﬁcant decrease in active caspase 3
staining in 4T1 cells cultured on matrices lacking Col3
(Col3/) after serum deprivation (Figure 4B). Similar trends
for proliferation and apoptosis were also seen in human
MDA-MB-231 breast cancer cells cultured on Col3-deﬁcient
matrices relative to wild-type matrices (Supplemental
Figure S2, A and B). Consistent with these in vitro ﬁndings,
tumor cell proliferation was signiﬁcantly increased and
apoptosis was signiﬁcantly decreased in 4T1 tumors grown in
Col3þ/ mice compared to Col3þ/þ littermates, as evidencedajp.amjpathol.org - The American Journal of Pathology
Figure 2 Orthotopic murine (4T1) mammary tumor growth and metastasis to the lung are limited by type III collagen (Col3). A: Tumor growth was
measured in 4T1 tumor-bearing (0.1  106 cells injected) female Col3þ/þ and Col3þ/ mice using calipers. B: To compare the cumulative pattern of
tumor growth, the area under the curve was calculated for each tumor. C: The mass of the tumors was determined at the time of sacriﬁce (day 24). D
and E: Hematoxylin and eosin (H&E) sections of lungs from Col3þ/þ and Col3þ/ mice bearing orthotopic 4T1 tumors. Arrows point to metastatic
nodules. Inset is magniﬁed in E. F: Gross metastases were counted on lung lobe surfaces. G: The number of metastatic nodules within H&E-stained
sections of all ﬁve bisected lung lobes of 4T1-bearing Col3þ/þ and Col3þ/ mice, as assessed by a board-certiﬁed pathologist (E.A.M.). H: Lung
metastatic tumor burden (tumor area over total lung area) was calculated from the same images in G using ImageJ software. Representative data from
ﬁve independent experiments with the injection of 0.1 to 5.0  106 cells all show increased metastases in Col3þ/ animals (quantitative data shown
after orthotopic injection of 0.1  106 4T1 cells). Data represent means  SEM (AeC and FeH). n Z 7 to 10 mice per genotype (AeC and FeH).
*P < 0.05 (AeC and FeH).
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Figure 3 Type III collagen (Col3) does not affect initial murine (4T1)egreen ﬂuorescent protein (GFP) cell adhesion and colonization in the lung. A: Col3
mRNA expression in lungs from young and aged mice relative to young Col3þ/þ lungs. B and C: 1.0  106 4T1-GFP cells were injected via the tail vein into
young adult Col3þ/þ and Col3þ/ mice. After 24 hours, lungs were harvested and processed into single-cell suspensions. The percentage live [propidium iodine
(PI)enegative] 4T1 cells (GFP positive) within the lung was quantiﬁed by ﬂow cytometry. Data represent means  SEM (A and C). nZ 4 Col3þ/þ and nZ 6
Col3þ/ (A, young mice); n Z 3 Col3þ/þ and n Z 3 Col3þ/ (A, aged mice); n Z 10 to 12 per genotype (C). **P < 0.01.
Brisson et alby Ki-67 and active caspase 3 staining, respectively (Figure 4,
CeF). Thus, both mechanisms (increased proliferation and
decreased apoptosis) contribute to increased primary tumor
growth in Col3þ/ mice compared to wild-type littermates.
Col3 Deﬁciency Promotes a Metastatic Phenotype
in Vitro
To mimic the effects of the tumor stroma in an in vitro sys-
tem, we co-cultured 4T1 cells with wild-type (Col3þ/þ) and
Col3/ mouse embryonic ﬁbroblasts. We observed a
marked increase in 4T1 cell numbers in the presence of
Col3/ ﬁbroblasts (Figure 5A). We also observed a striking
difference in 4T1 cell morphology (Figure 5A). Consistent
with cell morphology on tissue culture plastic, 4T1-GFP cells
co-cultured with wild-type (Col3þ/þ) ﬁbroblasts grew as ag-
gregates. In contrast, when co-cultured with Col3/ ﬁbro-
blasts, cells dispersed throughout the culture (Figure 5A).
Adhesion assays demonstrated that the number of adherent
4T1 cells was signiﬁcantly increasedwhen plated onto Col3/
ﬁbroblasts compared to Col3þ/þ ﬁbroblasts (Figure 5, B and
C), suggesting that this dispersed phenotype may, at least in
part, be due to Col3-dependent alterations in cell adhesion.
To determine whether Col3 directly affects adhesion or
whether this effect is instead mediated by modulation of
ﬁbroblast phenotype, we plated 4T1 cells in wells coated with
Col3, mixtures of Col1/3, or Col1. Even in the absence of
ﬁbroblasts, 4T1 adhesion was decreased on a Col3 substrate
compared to Col1 substrate alone (Figure 5D). Adhesion of
4T1 cells on a mixture of the two collagens (50:50, total
collagen constant) was intermediate between either collagen
alone. To ensure that the decreased adhesion of 4T1 cells was
due to an increase in Col3 rather than loss of Col1, we also
examined 4T1 adhesion on a collagen substrate of constant
Col1 and additional Col3 (Col1/3, 100:50). Even with an
increase in total collagen, the addition of Col3 signiﬁcantly
reduced 4T1 adhesion. Col3-induced changes in cell
spreading, attachment strength, and survival may have also
contributed to these ﬁndings given the 2-hour time points
used in this set of assays.1478Because the stiffness of the tumor microenvironment can
affect cell adhesion,58 we also compared adhesion of 4T1
cells to the ﬁbrillar collagens (Col1, Col3, or Col1/3, 50:50
mixture) on hydrogels of physiologically relevant stiffness
(6 kPa),41 which are signiﬁcantly softer than tissue culture
plastic. 4T1 cell adhesion to Col3-, Col1/3-, and Col1-
coated hydrogels again conﬁrmed that Col3 signiﬁcantly
reduced the number of attached 4T1 cells (Supplemental
Figure S3). Thus, on a matrix of biologically relevant
stiffness, Col3 directly reduces breast cancer adhesion.
Adhesion of human MDA-MB-231 cells was also signiﬁ-
cantly decreased on Col3 compared to Col1 (Supplemental
Figure S2C), thus supporting a shared response to Col3 by
triple-negative breast cancer cells in mice and humans.
Given the increased incidence of metastasis associated with
Col3 haploinsufﬁciency in the 4T1 model of murine breast
cancer, we examined the ability of Col3 to modulate invasion
and migration of breast cancer cells through basement
membrane gels supplemented with Col3, a 50:50 mixture of
Col1 and Col3, or Col1 alone using standard in vitro Trans-
well assays.59 Invasion of 4T1 or MDA-MB-231 cells was
signiﬁcantly inhibited in Col3-containing gels compared to
gels with Col1 alone (Figure 6, A and C, and Supplemental
Figure S2D). Similarly, the presence of Col3 resulted in a
signiﬁcant reduction in 4T1 and MDA-MB-231 cell migra-
tion (Figure 6, B and D, and Supplemental Figure S2E). Thus,
Col3 directly limits murine and human breast cancer cell in-
vasion and migration, supporting the hypothesis that Col3
suppresses metastatic escape at the level of the primary tumor.Col3 Deﬁciency Promotes a Procarcinogenic Stroma by
Regulating Collagen and Myoﬁbroblast Density and
Alignment
Collagen reorganization is increasingly recognized as a key
determinant of a procarcinogenic microenvironment, with
increasing collagen alignment facilitating metastasis.16,18,21,24
Compared to a complex or disorganized matrix, aligned
collagenprovides a directed pathway for tumor cells tomigrateajp.amjpathol.org - The American Journal of Pathology
Figure 4 A type III collagen (Col3)edeﬁcient microenvironment pro-
motes breast cancer cell proliferation and inhibits cell death. A: Proliferation
of murine (4T1) cells on Col3-rich and Col3-null native ﬁbroblast-derived
matrices was analyzed using a bromodeoxyuridine cell proliferation assay.
Four different littermate embryonic ﬁbroblast pairs (Col3þ/þ and Col3/)
were used to generate matrices. B: Apoptosis of 4T1 cells grown on Col3þ/þ
and Col3/ matrices after 48-hour serum starvation was analyzed by
immunoﬂuorescence staining for active caspase 3. Three littermate embryonic
ﬁbroblast pairs (Col3þ/þ and Col3/) were examined in triplicate (ﬁve im-
ages per well). C: Tumor sections from Col3þ/þ and Col3þ/mice were stained
for Ki-67 as a marker of proliferating cells. D: Proliferative index (percentage
Ki-67epositive nuclei) was calculated. E: Tumor sections from Col3þ/þ and
Col3þ/ mice were stained for active caspase 3 as a marker of apoptosis. F:
Active caspase 3 signal (active caspase 3epositive area) was calculated. For
both proliferation and apoptosis staining in tumors, ﬁve random images that
did not contain tumor edge or necrotic regions were taken per tumor. Data
represent means  SEM (D and F). n Z 7 tumors per genotype (D and F).
*P < 0.05. Original magniﬁcation,20 (C and E). ECM, extracellular matrix.
Col3 Suppresses Breast Cancer Metastasison and invade surrounding tissues. To determine whether
Col3 potentially regulates ﬁbrillar collagen production and
organization in the tumor stroma, we performed collagen SHG
imaging of ﬁbroblast-derived matrices (Figure 7A) and foundThe American Journal of Pathology - ajp.amjpathol.orgthat Col3/ ﬁbroblasts produced a more highly aligned and
ﬁbrillar matrix than wild-type cells (Figure 7, BeD). To
conﬁrm that Col3 regulates stromal organization of breast
cancer in vivo, 4T1 tumors were harvested from mice after 14
days. The H&E-stained tumor sections showed no obvious
differences in general tumor morphology between genotypes
(Figure 7E). However, when sectionswere imaged using SHG
(Figure 7F), the tumors from Col3-deﬁcient (Col3þ/) mice
contained more mature and aligned collagen ﬁbers than the
tumors from Col3þ/þ mice, similar to that seen with the
ﬁbroblast-derived matrices. Furthermore, at the tumor pe-
riphery, collagen ﬁbers exhibited a more invasive phenotype
characterized by alignment perpendicular to the tumor border
in Col3þ/ mice compared to that seen in Col3þ/þ mice
(Supplemental Figure S4). Stromal collagen density and or-
ganization at the tumor boundary can be characterized using
SHG to generate TACS scores. The invasiveTACS-3 has been
shown to correlate with aggressive behavior in murine breast
cancer models15,18,44 and has been established as an inde-
pendent prognostic indicator in women regardless of tumor
subtype, grade, and size, hormone receptor status, and lymph
node status.16,19,24 TACS analysis conﬁrmed a signiﬁcant
decrease in the noninvasive TACS-2 signature (P< 0.01) and
a signiﬁcant increase in the invasive TACS-3 signature
(P< 0.05) in tumors ofCol3-haploinsufﬁcientmice compared
to wild-type littermates (Supplemental Figure S4).
Given our previous ﬁnding that Col3 deﬁciency drives
myoﬁbroblast differentiation and scar formation after cuta-
neous injury,26 we next investigated whether Col3þ/ tu-
mors contained more myoﬁbroblasts than tumors in Col3þ/þ
mice. On the basis of expression of a-SMA, a marker of
myoﬁbroblasts (Figure 7, G and H), we found that tumors in
Col3þ/ mice had signiﬁcantly increased stromal myoﬁ-
broblast density. CD31 immunoﬂuorescence conﬁrmed that
most a-SMAepositive cells were not associated with
vascular smooth muscle cells (data not shown). In addition,
a-SMAþ cells were organized in a striking, highly aligned
pattern in the tumors of Col3þ/ compared to Col3þ/þ mice
(Figure 7I), suggesting that Col3 directs matrix organization
or the ability of ﬁbroblasts to interact with that matrix.
To determine Col3 expression and localization within the
stroma, we performed immunohistochemistry for Col3 in
tumors (14 days after orthotopic injection). Although there
was marked heterogeneity in the density of Col3 throughout
the tumors of both Col3þ/þ and Col3þ/ mice (Figure 8),
Col3 was found to be more aligned within tumors of Col3-
haploinsufﬁcient mice compared to wild-type littermates,
similar to overall ﬁbrillar collagen and myoﬁbroblast orga-
nization. Because multiple studies have shown that tumor
cells can contribute to stromal collagen production, we
investigated whether 4T1 cells produce Col1, Col3, or both.
Compared to Col3þ/þ ﬁbroblasts, neither Col3 nor Col1
expression could be detected in cultured 4T1 cells, even when
cultured on decellularized ﬁbroblast matrices from either
Col3þ/þ or Col/ ﬁbroblasts (Supplemental Figure S5). This
is consistent with a previous study showing that stromal Col31479
Figure 5 Murine (4T1) tumor cell morphology is changed and adhesion is enhanced in type III collagen (Col3)enull microenvironments. A:
Morphology of 4T1egreen ﬂuorescent protein (GFP) cells co-cultured with Col3þ/þ and Col3/ ﬁbroblasts in serum-free media for 48 hours. Four
different littermate embryonic ﬁbroblast pairs were analyzed (three representative pairs shown). B: Images of 4T1-GFP cells after 2 hours in co-culture
with Col3þ/þ and Col3/ ﬁbroblasts. C: Quantitative analysis of ﬁve different littermate embryonic ﬁbroblast pairs (three representative pairs shown
in B), evaluated in triplicate culture wells (ﬁve images per well). D: 4T1-GFP cells were allowed to attach for 2 hours to tissue culture plastic wells coated
with the following: 0.5 mg/cm2 Col3; a 50:50 mixture of Col1 and Col3 (Col1/3, 50:50; total collagen Z 0.5 mg/cm2); 0.5 mg/cm2 Col1; or a 100:50
mixture of Col1 and Col3 (Col1/3, 100:50; total collagenZ 0.75 mg/cm2). Attached cells were ﬁxed and stained with crystal violet and read at OD 570.
Data represent means  SD of three independent experiments (C and D). **P < 0.01 via a paired Student’s t-test (for comparisons between 4T1 cells on
Col3þ/þ and Col3/ ﬁbroblasts; C); *P < 0.05, **P < 0.01 via one-way analysis of variance, followed by Tukey post hoc test (for comparisons between
Col3, Col1/3, and Col1; D). Original magniﬁcation, 10 (A and B).
Brisson et alproduction was limited to ﬁbroblasts in late-stage human
mammary carcinoma biopsy specimens, assessed by in situ
hybridization, and that malignant epithelial cells did not
contribute to stromal Col3,60 although it is possible that 4T1
cells do express some ﬁbrillar collagens in vivo. As expected,
Col3 expression in Col3/ ﬁbroblasts was not detectable.
Consistent with increased ﬁbrillar collagen production in the
tumors of Col3þ/ mice, there was a trend for increased
Col1 expression in cultured Col3/ compared to Col3þ/þ
ﬁbroblasts. The lack of a more dramatic effect on Col1 levels
suggests that the major effect of Col3 was on matrix organi-
zation, although temporal changes in Col1 may lead to1480signiﬁcant changes at later times. Together, our data indicate
that Col3 suppresses a tumor-inciting stroma and provide
strong support for the hypothesis that a Col3-deﬁcient
microenvironment promotes breast cancer metastasis.
Discussion
We show herein that Col3 suppresses metastatic behavior of
triple-negative breast cancer cells in vitro and primary tumor
growth and metastasis of 4T1 cells in vivo. This is in marked
contrast to the tumor- and metastases-promoting behavior of
the related ﬁbrillar Col1. Furthermore, we deﬁne aajp.amjpathol.org - The American Journal of Pathology
Figure 6 Type III collagen (Col3) impairs murine (4T1) tumor cell invasion and migration. A and C: 4T1 cells were allowed to invade through a basement
membraneelike gel (Matrigel) supplemented with Col3, a 50:50 mixture of Col1/Col3 (Col1/3), or Col1, and through a porous membrane for 16 hours. Cells that
had invaded through the gel and the membrane were stained with crystal violet, imaged, and read at OD 570. B and D: Migration experiments were performed
as in A and C, except no Matrigel was included and instead the collagens were used to coat the membranes. Crystal violetestained cells appear dark in images
A and B, revealing less invasion and migration in response to a Col3-rich environment. *P < 0.05 via one-way analysis of variance, followed by Tukey post hoc
test (for comparisons between Col3, Col1/3, and Col1).
Col3 Suppresses Breast Cancer Metastasispreviously unreported role for Col3 in regulating matrix
organization within the tumor stroma. These data comple-
ment our previous ﬁnding that Col3 plays a unique role,
distinct from Col1, in promoting a regenerative response
after cutaneous injury and limiting scar formation,26 and are
consistent with previously published data showing that
robust expression of Col3 correlates with improved survival
of human breast cancer patients.32
Interactions between malignant mammary cells and the
surrounding peritumoral stroma play a critical role in mam-
mary tumor progression. Dysregulated ECM dynamics are a
deﬁning feature of malignancy, and increased stromal
collagen correlates with both increased breast cancer risk and
poor prognosis.4,13e15 In addition, the organization and
stiffness of the collagenmatrix are keymediators ofmammary
tumor growth and invasion.16,18,19,21e24 Aberrant collagen
composition, topography, and stiffness can initiate a pro-
carcinogenic niche that promotes local tumor invasion and
subsequent metastasis through its effects on proliferation,
apoptosis, adhesion, invasion, andmigration.1,7,22,24,61,62 Our
results show that the collagen from Col3/ ﬁbroblasts and
within tumors of Col3-deﬁcient mice is denser and more
highly aligned than in wild-type counterparts (Figure 7) and
that this Col3-deﬁcient matrix promotes a tumor-permissive
microenvironment (Figures 4, 5, and 6 and Supplemental
Figures S2 and S3) that leads to increased primary tumorThe American Journal of Pathology - ajp.amjpathol.orggrowth and metastasis (Figure 2). Notably, tumors in Col3þ/
mice were found to have signiﬁcantly increased TACS-3 sig-
natures compared to those from wild-type littermates
(Supplemental Figure S4). TACS-3 has been previously shown
to correlate with invasive tumor behavior and poor prognosis in
women, as well as murine models.15,16,18,19,24 Given the role of
Col3 in regulating collagen alignment, it is possible that Col3
deﬁciency may also increase stromal stiffness, which is known
to promote aggressive breast cancer behavior,22 although stiff-
ness was not examined in the current study.
Our work deﬁnes a role for Col3 in regulating collagen
organization both in vitro and in vivo. Previously, we have
shown that Col3 deﬁciency during cutaneous wound healing
results in an increase and persistence of granulation tissue
myoﬁbroblasts and a subsequent increase in scar tissue
deposition.26 Similarly, in the tumor microenvironment
studied herein, a reduction in Col3 resulted in a robust and
aligned SHG signal (Figure 7). Our data also show an
increase in density and alignment of a-SMAepositive
myoﬁbroblasts in tumors of Col3-haploinsufﬁcient mice.
These increased myoﬁbroblast numbers may be secondary
to Col3 modulation of myoﬁbroblast recruitment, increased
proliferation or attenuated apoptosis (similar to what we
show in the tumor cells), or a combination of these pro-
cesses. Although it is possible that these myoﬁbroblasts are
responsible for further remodeling of theCol3-deﬁcientmatrix1481
Figure 7 Type III collagen (Col3) deﬁciency alters collagen matrix in ﬁbroblast-derived matrices and the stromal matrix and increases myoﬁbroblast
density and alignment in murine (4T1) tumors. A: Second harmonic (SHG) two-photon imaging was used to analyze the ﬁbrillar collagen intensity and or-
ganization in Col3þ/þ and Col3/ ﬁbroblast-derived matrices. White signal represents collagen ﬁbers. Fibroblasts were isolated from six embryos. B: Collagen
signal intensity (percentage SHG-positive area; ﬁve images taken per individual ﬁbroblast matrix) was analyzed using ImageJ software. C: Linearity was
analyzed by generating fast Fourier transform (FFT) plots in ImageJ software for each image. Signal that produced a more elongate ellipse represents more
aligned, organized ﬁbers. D: Linearity was calculated using the FFT plots. E: Hematoxylin and eosin sections of 14-day-old tumors (0.5  106 cells injected). F:
SHG imaging was used to visualize the ﬁbrillar collagen in central portions of parafﬁn-embedded 4T1 tumor sections from Col3þ/þ and Col3þ/ mice. G:
Sections of 4T1 tumors from Col3þ/þ and Col3þ/ mice (seven per genotype) were stained for a-smooth muscle actin (a-SMA), to label myoﬁbroblasts. Five
random images that did not contain tumor edge were taken per tumor. Representative images are shown. Green, a-SMA; blue, DAPI. H and I: ImageJ software
was used to quantify the intensity of a-SMA staining (a-SMAepositive area; H) and alignment (I). Data represent means  SEM. nZ 3 Col3þ/þ and Col3/
embryos (A). *P < 0.05, **P < 0.01, and ***P < 0.001. Original magniﬁcation, 20 (EeG). ECM, extracellular matrix.
Brisson et alinto a more highly aligned matrix, recent data demonstrating
that increasing the percentage of Col3 within Col1 gels de-
creases the density and alignment of ﬁbrillar collagen
in vitro,20 paired with the SHG studies presented herein,
support an important role for Col3 in modulating ﬁbrillar
collagen organization.
The ability of Col3 to decrease collagen network organi-
zation likely contributes to its ability to suppress tumor
progression21 and is supported by a signiﬁcant increase in
TACS-3 score development in Col3-deﬁcient (Col3þ/)
mice. In support of Col3 serving as a gatekeeper to prevent
cancer cell escape from the primary tumor, our results from
in vitro assays reveal signiﬁcant Col3-dependent reductions
in adhesion, invasion, andmigration. Similar Col3-dependent
suppressive effects on these metastatic processes were found
in the human MDA-MB-231 breast cancer cells. Given the
relatively modest effect (15% to 40% reduction) in any one
process and the much greater (twofold to threefold) effects
seen on tumor growth and metastasis in vivo, our data suggest
that Col3 regulation of breast cancer behavior is complex and
multifaceted. Althoughwe did not see a signiﬁcant increase in
tumor cell colonization of Col3-deﬁcient lungs using the tail
vein injection assay (Figure 3), it is possible Col3 deﬁciency1482in the metastatic niche may still play an important role in
regulating metastasis given limitations of this assay. These
limitations include limited analysis of the postextravasation
process, lack of analysis in the nonpulmonary metastatic
niche, and lack of primary tumor presence that may inﬂuence
the premetastatic microenvironment.63,64
Human vascular Ehlers-Danlos syndrome patients have
mutations in the Col3a1 gene and have decreased levels of
Col3.65,66 There are no reports that these patients have an
increased risk of cancer, or that they develop more aggressive
cancers; however, vascular Ehlers-Danlos syndrome is a rare
syndrome and patients have a decreased life span. The risk of
cancer in these patients should be studied systematically,
because data presented herein suggest that reduced, and not
completely absent, tissue Col3 levels may signiﬁcantly affect
breast cancer outcomes. Notably, a large, and growing, popu-
lation of women at risk for breast cancer may develop an ac-
quired loss of Col3 secondary to smoking, advancing age, the
postmenopausal state, and common medications (eg,
steroids).34,54e57,67e69 An age-associated reduction in Col3 in
both the lungs (Figure 3A) and in bone34 (two common sites for
breast cancer metastasis) in wild-type mice is consistent
with levels seen in the young Col3-haploinsufﬁcient modelajp.amjpathol.org - The American Journal of Pathology
Figure 8 Stromal type III collagen (Col3) density is heterogeneous
within murine (4T1) tumors but is localized to the aligned matrix within
tumors of Col3þ/ mice. A: mRNA expression of Col3 in 14-day tumors in
Col3þ/þ and Col3þ/ mice. B: Images of Col3-stained tumors from Col3þ/þ
and Col3þ/ mice showing the heterogeneity in the amount of Col3 staining
but the consistent alignment of Col3-containing matrix in tumors of Col3þ/
mice. Representative images are from similar regions not containing tumor
edge or necrosis. Boxed areas are enlarged in C. C: Images of Col3-stained
tumors. n Z 4 Col3þ/þ and Col3þ/ (A). Scale bar Z 100 mm (B and C).
Original magniﬁcations: 20 (B); 60 (C).
Col3 Suppresses Breast Cancer Metastasisused in this study, providing further support for this model.
Therefore, understanding mechanisms by which Col3 loss
leads to increased breast cancer aggressiveness could
provide novel targets for intervention in many breast
cancer patients.
Although expression of Col3, as a component of a stro-
mal signature, has been linked to improved survival ofThe American Journal of Pathology - ajp.amjpathol.orgbreast cancer patients, expression of Col3 has yet to be
clearly deﬁned as a prognostic marker. In part, this may be
due to the enhanced density of myoﬁbroblasts, which may
produce Col3. Thus, in Col3-deﬁcient tissue, the evolution
of the collagen component of the tumor stroma due to dy-
namic reciprocity between the ECM, tumor, and stromal
cells may ultimately lead to increasing levels of Col3 over
time, even though the initial expression of Col3 was low.
Col3 production by reactive ﬁbroblasts in malignant breast
tumors was demonstrated by a previous study examining
collagen expression in late-stage malignant breast tumor
biopsy specimens.60 The dynamic nature of the collagen
expression is supported by a lack of signiﬁcant difference in
tumor Col3 at day 14 after orthotopic injection (Figure 8).
Spatiotemporal variations in Col3 in the evolving tumor
microenvironment may reduce its utility as a prognostic
marker at the time of biopsy and may explain why more
studies have yet to identify an association between Col3 and
prognosis in breast cancer patients. Nonetheless, our data
support that Col3 deﬁciency is a critical contributor to the
procarcinogenic microenvironment early in the course of
breast cancer through its ability to direct matrix organization
that supports metastasis from the primary tumor. In addition,
although our data suggest that colonization by metastatic
cells is unchanged in Col3-deﬁcient versus wild-type mice,
cells that do adhere may have a survival advantage if in a
Col3-deﬁcient niche. As such, our identiﬁcation of a role for
Col3 in tumor suppression may aid in identifying patients
most at risk for aggressive disease and deﬁning targets for
therapy for those with microscopic disease.
Most studies supporting the tumor-permissive properties
of a collagen-rich tumor stroma have focused on Col1.
Although Col1 clearly plays a role in regulation of tumor
behavior, the reference to Col1 as stromal collagen may be
unwarranted because it implies similar function of all col-
lagens within the tumor microenvironment. Interestingly,
another ﬁbrillar collagen, type V collagen, has been shown
to induce breast cancer cell apoptosis.70 Because of the
increasing evidence that the collagen component of the
tumor microenvironment plays a key role in directing cancer
behavior,4,13e16,18,19,24 there has been great interest in
exploiting antiﬁbrotic agents for use in oncology patients.
Notably, our data suggest that nonselective antiﬁbrotic
agents that decrease production of Col3 may be detri-
mental and instead suggest that agents selectively target-
ing Col1 while preserving Col3 may be more beneﬁcial
therapeutically.
Taken together, our data indicate that Col3 plays a pre-
viously unrecognized and important role in suppressing
primary tumor growth and metastasis in a murine model of
triple-negative breast cancer. Clinical relevance is supported
by our results using a human breast cancer cell line and
previous data suggesting that a stromal response which in-
cludes robust expression of Col3, is related to improved
clinical outcome in women with breast cancer.32 We predict
that Col3 may have a more global role in regulating cancer1483
Brisson et alprogression and warrants additional investigation. Finally,
given its previously deﬁned properties in wound healing,
Col3-containing biomaterials applied after excisional biopsy
may provide a safe and effective strategy to simultaneously
improve healing and limit local recurrence, which has been
shown to negatively affect long-term prognosis in breast
cancer patients.71 A better understanding of the mechanisms
by which Col3 regulates tumor growth and metastasis may
provide novel therapeutic approaches for cancer patients and
ensure safety of emerging therapies.
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